UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 3, 2003
IMMTECH INTERNATIONAL, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 8733 39-1523370
--------------------------------------------------------------------------------
(State or Other (Commission File Number) (I.R.S. Employer
Jurisdiction of Identification No.)
Incorporation)
150 Fairway Drive, Suite 150, Vernon Hills, Illinois 60061
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (847) 573-0033
-----------------------
Not Applicable
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On November 26, 2003, Immtech International, Inc. ("Immtech")
entered into a Testing Agreement with Medicines For Malaria Venture, a
foundation established in Switzerland ("MMV") and The University of North
Carolina at Chapel Hill, a public institution of higher education with
administrative offices at Chapel Hill, North Carolina, United States of America
("UNC"), pursuant to which Immtech, with the support of MMV and UNC, will
conduct a proof of concept study of the dicationic drug candidate DB289,
including Phase II and Phase III human clinical trials, and will pursue drug
development activities of DB289 alone, or in combination with other
anti-malarial drugs, with the goal of obtaining marketing approval of a product
for the treatment of malaria.
Under the terms of the agreement, MMV has committed to advance funds
to Immtech to pay for human clinical trials and regulatory preparation and
filing costs for the approvals to market DB289 for treatment of malaria by at
least one internationally accepted regulatory body and one malaria endemic
country. Immtech has forecasted such costs to be approximately $8.2 million over
the next three years. MMV has agreed to fund the forecasted amount based on
progress achieved, including payment to Immtech of approximately $668,000 in
respect of human clinical trials conducted in 2003. UNC will receive
approximately $50,000 for its work to evaluate synergistic qualities of other
drugs that may be used in combination with DB289 as a malarial drug "cocktail".
Attached below is Exhibit 10.1, the Testing Agreement effective as
of November 26, 2003, among Medicines for Malaria Venture, Immtech International
Inc., and The University of North Carolina At Chapel Hill.
The following exhibits are filed with this report:
Exhibit Number Description
-------------- -----------
10.1 Testing Agreement effective as of November 26, 2003 among
Medicines for Malaria Venture, Immtech International Inc.,
and The University of North Carolina at Chapel Hill
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
IMMTECH INTERNATIONAL, INC.
By: /s/ T. Stephen Thompson
---------------------------------------
Name: T. Stephen Thompson
Title: Chief Executive Officer and
President
Dated: December 3, 2003